Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-354-0 | CAS number: 18472-51-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2007-03-28 to 2007-10-10
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- D-gluconic acid, compound with N,N''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine (2:1)
- EC Number:
- 242-354-0
- EC Name:
- D-gluconic acid, compound with N,N''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine (2:1)
- Cas Number:
- 18472-51-0
- Molecular formula:
- C22H30Cl2N10.2C6H12O7
- IUPAC Name:
- N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)] - D-gluconic acid (1:2)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD/Crl:CD (SD)
- Details on test animals or test system and environmental conditions:
- Strain / Stock: CD® / Crl: CD (SD)
Adaptation period: 6 days
Age (on day 0 of pregnancy): 8 - 10 weeks
Body weight (on day 0 of pregnancy): 198 - 289 g
Diet: Commercial ssniff(R) R-Z V1324 ad lib.
Housing: Except during the mating period, the dams were kept singly in MAKROLON cages
Room temperature: 22°C ± 3°C
Relative humidity: 55% ± 15%
12 hours dark/12 hours light cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analysis of the test item-carrier mixtures gave 92.5 to 100.6 % of the nominal values.
- Details on mating procedure:
- Sexually mature ('proved') male rats of the same breed served as partners. The male and female breeding partners were randomly chosen. Mating was monogamous: 1 male and 1 female animal were placed together in one cage during the dark period. Each morning a vaginal smear was taken to check for the presence of sperm and the stage of oestrus cycle. If findings were negative, mating was repeated with the same partner. The day on which sperm was found was considered as the day of conception (day 0 of pregnancy). This procedure was repeated until enough pregnant dams were available for all groups. Rats which did not become pregnant were excluded from the analysis of the results and replaced by other animals. A post-mortem negative staining according to SALEWSKI was carried out in the replaced animals in order to confirm the non-pregnancy status.
- Duration of treatment / exposure:
- day 6 to 19 of gestation
- Frequency of treatment:
- once daily
- Duration of test:
- necropsy at day 20 of gestation
- No. of animals per sex per dose:
- 4 groups with 25 females each. Evaluated litters: 20 per group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale: Based on a dose-range-finding study
Examinations
- Maternal examinations:
- Clinical signs:
Individual animals were observed daily for mortality, behaviour, external appearance and nature of the faeces.
Body weight:
The weight of each rat was recorded on day 0 of gestation followed by daily weighings. The body weight gain was also calculated in intervals.
Food and drinking water consumption:
The quantity of food consumed per rat was recorded daily with the exception of gestation day 20 (necropsy). Also the relative food consumption (g/kg bw/d) was calculated. - Ovaries and uterine content:
- Examinations at necropsy (day 20):
Removal of ovaries and uteri of the dams. Uteri (in toto) were weighed. Dissection with macroscopic examination of the internal organs and placentae of the dams at necropsy or on the day on which the animals were found dead. In case of macroscopical findings, the affected maternal tissues were preserved in 7% buffered formalin for possible future histopathological examinations.
The fetuses were removed and the following examinations performed:
-Macroscopic inspection (gross evaluation) of the placentae.
-Determination a.) of the number of fetuses and % per dam (alive and dead) and placentae, b.) of sex and viability of fetuses, c.) of number and size of resorptions, d.) of corpora lutea in the ovaries, implantations and location of fetuses in the uterus and e.) of gravid uterus weights, weights of fetuses and weights of placentae. - Fetal examinations:
- Fetuses were inspected externally for damages, especially for malformations. 50 % of the number of fetuses in each litter were examinded for skeletal anomalies, while the remaining 50 % were examined for soft tissue anomalies.
Evaluation/parameters: sex ratio per litter, distribution in the uterine horns, absolute and mean number of fetuses alive per group, mean % of fetuses alive per group, mean % per sex and group, runts, fetuses with variations or retardations, retardation rate, and pre- and post-implantation loss. - Statistics:
- BARTLETT chi-square test, DUNNETT test, STUDENT's t-test, FISHER's exact test and chi2-test with YATES' correction for continuity
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Mortality:
None of the dams treated died prematurely.
Clinical signs:
Laboured breathing on several test days in one dam dosed with 30 mgkg bw/d. Pilo-erection and/or laboured breathing on one to several test days in 8 of 21 dams dosed with 100 mg/kg bw/d, pre-dominantly during the second half of gestation until end of treatment. Further findings in these dams were a haemorrhagic nose in two females and reduced motility in one rat on two or three treatment days.
Body weight:
No adverse effects at <= 30 mg/kg bw/d. Dosing with 100 mg/kg bw/d caused a reduction from gestation day 9 onwards until end of study. Significant reductions for mean maternal body weights of high-dosed dams on gestation days 9 to 20, for mean maternal body weight changes on gestation days 6 to 9 and 9 to 12 and for the net weight change from day 6 onwards.
Food consumption:
Reduced relative food intake in dams dosed with 100 mg/kg bw/d on gestation days 7 to 13.
Drinking water consumption:
No adverse effects in treated animals.
Necropsy findings:
Necropsy revealed no pathological findings in treated animals.
Significant reductions in uterus and carcass weights in dams dosed with 100 mg/kg bw/d.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 30 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
Corpora lutea / implantation sites / resorptions / weight and number of live fetuses / placental weights:
No adverse effects on prenatal fetal development at doses of <= 30 mg/kg bw/d.
No dead fetuses or runts at termination of the study.
At the materno-toxic dose of 100 mg/kg bw/d, significant increases were noted for early, late and total resorptions and the number of fetuses was significantly reduced. There was also a slight decrease in fetal weights.
Malformations / Variations:
No adverse effects at any dose level.
Retardations:
At the materno-toxic dose of 100 mg/kg bw/d, the following effects were noted: retarded ossification for sternebra(e) (not ossified), caudal vertebral bodies (no body ossified), thoracic vertebral bodies (less than 13 bodies ossified), pelvic vertebral bodies (less than 5 bodies ossified), 5th metatarsalia (absence of ossification) and os ischii (not ossified).
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 30 mg/kg bw/day
- Basis for effect level:
- other: embryotoxicity
- Dose descriptor:
- NOAEL
- Effect level:
- > 100 mg/kg bw/day
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- No teratogenic properties were noted during external/internal, skeletal and soft tissue examination up to the materno-toxic dose of 100 mg chlorhexidine digluconate/kg bw/d. There was no increase in the incidence of fetal malformations or variations. At the materno-toxic dose of 100 mg/kg bw/d, slight embryotoxic properties were noted in form of reduced fetal weights and increased incidences of skeletal retardations.
- Executive summary:
In this prenatal developmental toxicity study, chlorhexidine digluconate was administered to female rats at dose levels of 0, 10, 30 or 100 mg/kg bw/d via gavage from the 6th to 19th day of gestation. First signs of maternal toxicity included laboured breathing at >= 30 mg/kg bw/d, while at 100 mg/kg bw/d pilo-erection, a haemorrhagic nose and/or reduced motility were noted. Furthermore, reductions were noted for the body weight, the net weight change and the food intake. The NOAEL for the fetuses was 30 mg/kg bw/d.
At the materno-toxic dose of 100 mg/kg bw/d, significant increases were noted for early, late and total resorptions and the number of fetuses was significantly reduced. In addition, slight reductions were noted for the fetal weights. The skeletal examination gave significantly increased fetal and/or litter incidences for skeletal retardations. The treatment caused no malformations or variations at any of the tested dose levels.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.